The power of comparative studies
- 31 May 2009
- journal article
- editorial
- Published by Elsevier BV in Leukemia Research
- Vol. 33 (5), 610-612
- https://doi.org/10.1016/j.leukres.2008.09.031
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- The Predictive Value of a “Positive” ASH Abstract in AML Therapeutics.Blood, 2006
- Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemiaLeukemia Research, 2006
- Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationTransplantation and Cellular Therapy, 2005
- New designs for phase 2 clinical trialsBlood, 2003
- The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the LiteratureLeukemia & Lymphoma, 2002
- Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemiaLeukemia Research, 2000
- A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemiaLeukemia, 1997
- Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.Journal of Clinical Oncology, 1991
- PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIALThe Lancet, 1986
- A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferationBlood, 1980